Pfizer Shareholders Lost 8.8% Over Five Years Despite Dividends

Pfizer (PFE) shareholders experienced a total return loss of 8.8% over the five-year period ending October 19, 2026, despite receiving dividend payouts that added 21.2 percentage points to their results. The company's stock price declined 30.0% during this interval, a performance that trailed the S&P 500's 76.3% price gain by 106.3 percentage points.

The dividend yield stood at 5.8% at the October 19, 2026 close, serving as the primary component of positive return for investors during the period of price erosion. While the cash payments reduced the overall loss significantly compared to a price-only calculation, they did not transform the investment into a profitable outcome. The S&P 500, measured through the SPDR S&P 500 ETF, generated a total return of 88.1% over the same timeframe. This left Pfizer holders 96.9 percentage points behind the broad market index, even after accounting for dividend reinvestment.

Pfizer’s dividend contribution outpaced that of the market index in absolute terms. The pharmaceutical company's payouts added nearly twice the 11.7 points generated by S&P 500 dividends. However, this extra cash flow recovered only about 9 percentage points of the initial price shortfall. Consequently, Pfizer’s dividends closed less than a tenth of the gap created by its underperformance relative to the broader market.

Recent performance has shown improvement for income-focused investors. Over the past year, Pfizer’s share price rose 21.5%, resulting in a total return of 30.0% when dividends are included. This compared favorably to the S&P 500's 17.0% return over the same period. Dividends added 8.5 percentage points to Pfizer's one-year return, whereas they contributed approximately one point to the index's performance.

The cash flow supporting these dividends derives from medicine sales, with Biopharma accounting for 97.8% of Pfizer’s revenue in fiscal 2025. During an August 4, 2026 earnings call, management stated that Pfizer remains committed to maintaining and growing its dividend over time. Investors monitoring the disparity between Pfizer’s total return and the S&P 500 will look to the company's next report, expected on or around November 3, 2026, for further updates on financial performance.